6000-59-5

Basic information

• Product Name: glyoxylic acid hydrate
• Synonyms: Glyoxalic Acid Hydrate;Acetic acid, oxo-, hydrate (2:1);Glyoxylsure-Monohydrat
• CAS NO: 6000-59-5
• Molecular Formula: C₂H₂O₃*H₂O
• Molecular Weight: 92.05076
• Product Categories: Pharmaceutical Intermediates
• Mol File: 6000-59-5.mol

Chemical Properties

• Melting Point: 48-52℃
• Boiling Point: 300.934°C at 760 mmHg
• Flash Point: 150.027°C
• Appearance: /
• Vapor Pressure: 0mmHg at 25°C
• Water Solubility: Freely soluble
• CAS DataBase Reference: glyoxylic acid hydrate(CAS DataBase Reference)
• NIST Chemistry Reference: glyoxylic acid hydrate(6000-59-5)
• EPA Substance Registry System: glyoxylic acid hydrate(6000-59-5)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R41:; R43:
• Safety Statements: S24:; S26:; S37/39:
• Hazardous Substances Data: 6000-59-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Glyoxylic acid hydrate is used as a key intermediate in the production of various pharmaceuticals for its ability to undergo chemical reactions that facilitate the synthesis of desired compounds.
Used in Agrochemical Industry:
Glyoxylic acid hydrate is used as a key intermediate in the production of agrochemicals, contributing to the development of effective and efficient products for agricultural applications.
Used in Fine Chemicals Industry:
Glyoxylic acid hydrate is used as a key intermediate in the synthesis of fine chemicals, enabling the creation of high-quality specialty chemicals for various applications.
Used in Cosmetics Industry:
Glyoxylic acid hydrate is used as a component in the manufacture of hair straightening products, dyes, and perfumes, leveraging its reactive properties to achieve desired effects in these products.

InChI:InChI=1/C2H4O4/c3-1(4)2(5)6/h1,3-4H,(H,5,6)/p-1

Upstream product

• 87-69-4 L-Tartaric acid 

Downstream Products

• 79002-45-2 N-benzyloxycarbonyl-glycine 
• 122399-84-2 4-[4-(4-Chloro-benzyloxy)-phenyl]-2-hydroxy-4-oxo-butyric acid 
• 40834-42-2 5-hydroxy-4-methyl-5H-furan-2-one 
• 101975-07-9 6-(4-trifluoromethoxyphenyl)-3[2H]pyridazinone 
• 68485-83-6 7-(1-Hydroxy-1-p-bromophenacyloxycarbonylmethyl)-8-oxo-7-azabicyclo[4.2.0]oct-3-ene 
• 68485-66-5 7-(1-phthalidyloxycarbonyl-1-triphenylphosphoranylidenemethyl)-8-oxo-7-azabicyclo[4.2.0]oct-3-ene 
• 90125-51-2 2-hydroxy-4-oxo-4-(2-hydroxyphenyl)butyric acid 
• 107580-81-4 (Z,Z)-4-(7,10-hexadecadienyl)-5-hydroxy-2(5H)-furanone 
• 50614-41-0 (E)-4-oxo-4-(3-(Trifluoromethyl)phenyl)but-2-enoic acid 
• 27738-46-1 3,4-(methylenedioxy)mandelic acid 
• 119742-20-0 N-formyl-N-(diphenylmethyl)glycine 
• 30439-19-1 5-methoxy-1,2,3,4-tetrahydro-9H-pyrido<3,4-b>indole 
• 1352450-78-2 2-(benzo[b]thiophen-3-yl)-2-(phenylamino)acetic acid 
• 1352451-04-7 2-(3-(ethoxycarbonyl)phenylamino)-2-(6-methoxypyridin-3-yl)acetic acid 

Relevant articles and documents

Production and Isomeric Distribution of Xanthylium Cation Pigments and Their Precursors in Wine-like Conditions: Impact of Cu(II), Fe(II), Fe(III), Mn(II), Zn(II), and Al(III)

This study establishes the influence of Cu(II), Fe(II), Fe(III), Zn(II), Al(III), and Mn(II) on the oxidative production of xanthylium cations from (+)-catechin and either tartaric acid or glyoxylic acid in model wine systems. The reaction was studied at 25 °C using UHPLC and LC-HRMS for the analysis of phenolic products and their isomeric distribution. In addition to the expected products, a colorless product, tentatively assigned as a lactone, was detected for the first time. The results show the importance of Fe ions and a synergistic influence of Mn(II) in degrading tartaric acid to glyoxylic acid, whereas the other metal ions had minimal activity in this mechanistic step. Fe(II) and Fe(III) were shown to mediate the (+)-catechin-glyoxylic acid addition reaction, a role previously attributed to only Cu(II). Importantly, the study demonstrates that C-8 addition products of (+)-catechin are promoted by Cu(II), whereas C-6 addition products are promoted by Fe ions.

HIV INTEGRASE INHIBITORS

The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.